Ripotinib belongs to several generations of targeted drugs. Is it available in China?

Repotrectinib (Repotrectinib), as a new generation of tyrosine kinase inhibitor (TKI) targeted drug, has attracted widespread attention in the field of cancer treatment. With its high selectivity, it can accurately target tumor cells with ROS1 and NTRK gene fusions, inhibiting their growth and spread. At the same time, raptinib also has the ability to overcome resistance to other TKI drugs, providing new treatment hope for patients who are no longer sensitive to traditional treatments. The development and application of this drug marks a major advancement in the field of cancer treatment.

At present, Ripotinib has been approved for marketing in my country, providing a new treatment option for domestic cancer patients. However, due to its relatively short time on the market, market supply may not have fully caught up with demand, resulting in some pharmacies still being out of stock, causing some patients who urgently need the drug to face certain difficulties. For this group of patients, they can consider purchasing drugs overseas through formal channels, but they need to pay attention to identifying the authenticity of the drugs to ensure their safety.

In overseas markets, the original research version of Ripotinib is produced by Bristol-Myers Squibb Company, with a specification of A box of 40mg*120 tablets sells for about 140,000 yuan, which is relatively expensive. The generic version launched by Laos Lucius Pharmaceutical Company provides another option for some patients with its more affordable price. A box of 40mg*60 pills is priced at just over RMB 3,000. However, it should be noted that due to exchange rate and other factors, the selling price of overseas drugs may change slightly.

In short, the launch of repotinib provides a new treatment option for domestic cancer patients. Although there are still some problems in market supply and price, it is believed that these problems will be gradually solved as time goes by and the market matures. For patients, it is important to obtain medications through formal channels to ensure their safety and effectiveness.

References:

https://www.drugs.com/history/augtyro.html